Cycloph 500 mg (Cyclophosphamide) Injection

Introduction to Cycloph 500 mg (Cyclophosphamide) Injection

Cycloph 500 mg, containing the active ingredient Cyclophosphamide, is a high-potency alkylating chemotherapy injection used to treat a broad spectrum of cancers, including malignant lymphomas, leukemias, multiple myeloma, and solid tumors like breast and ovarian carcinomas. Manufactured by Eskayef Pharmaceuticals Ltd. and supplied globally by Saif Pharma, this cytotoxic agent disrupts cancer cell DNA replication, offering proven efficacy in both monotherapy and combination regimens.

Key Indications & Therapeutic Benefits

Cycloph 500 mg is indicated for:

• Malignant Lymphomas: Hodgkin’s disease, Burkitt’s lymphoma, lymphocytic/histiocytic lymphoma (Stages III-IV).
• Leukemias: Chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML).
• Multiple Myeloma: Management of plasma cell disorders.
• Solid Tumors: Neuroblastoma, ovarian adenocarcinoma, retinoblastoma, and breast carcinoma.
• Mycosis Fungoides: Advanced cutaneous T-cell lymphoma.

Mechanism of Action: Cyclophosphamide is metabolized in the liver to active alkylating metabolites, which cross-link DNA strands, inhibiting cancer cell proliferation and inducing apoptosis.

Pharmacology & Pharmacokinetics

• Chemical Class: Nitrogen mustard alkylating agent.
• Metabolism: Activated in the liver by cytochrome P450 enzymes to phosphoramide mustard, the active metabolite.
• Excretion: Primarily renal (60-80%), with a half-life of 3–12 hours.
• Protein Binding: Low (10–20%), enabling widespread tissue distribution.

Recommended Dosage & Administration

Adults and Pediatric Patients:

• Monotherapy:
  • 40–50 mg/kg IV divided over 2–5 days.
  • Alternative regimens: 10–15 mg/kg every 7–10 days or 3–5 mg/kg twice weekly.
• Combination Therapy: Dose reductions required when used with other cytotoxic drugs (e.g., anthracyclines, taxanes).

Administration Guidelines:

1. Hydration: Force diuresis with 2–3 liters of fluids daily to prevent hemorrhagic cystitis.
2. IV Preparation:
   • Direct Injection: Dilute to 20 mg/mL using 0.9% NaCl, 0.45% NaCl, or 5% dextrose.
   • Infusion: Dilute to 2 mg/mL; avoid hypotonic solutions (e.g., sterile water).
3. Infusion Rate: Administer slowly to minimize adverse reactions (e.g., facial swelling, headache).

Storage:

• Unopened Vials: Store at 2–8°C; protect from light.
• Post-Dilution: Use within 24 hours at 2–8°C or 6 hours at 25°C.

Contraindications & Safety Warnings

• Hypersensitivity: Avoid in patients allergic to cyclophosphamide or nitrogen mustards.
• Urinary Obstruction: Contraindicated if urinary outflow is blocked.

Critical Warnings:

1. Myelosuppression: Severe neutropenia, thrombocytopenia, and anemia may occur. Monitor CBC weekly.
2. Immunosuppression: Increases risk of fatal infections (bacterial, viral, fungal).
3. Cardiotoxicity: Rare but fatal myocarditis, arrhythmias, or heart failure. Monitor cardiac function in high-risk patients.
4. Pulmonary Toxicity: Pneumonitis or fibrosis may lead to respiratory failure.
5. Secondary Malignancies: Long-term use linked to bladder cancer and myelodysplasia.

Common Side Effects

• Hematologic: Neutropenia (90%), febrile neutropenia (20%), anemia (50%).
• Gastrointestinal: Severe nausea/vomiting (70%), diarrhea (30%), anorexia.
• Dermatologic: Alopecia (80%), skin pigmentation changes.
• Renal/Bladder: Hemorrhagic cystitis (15%), dysuria, hematuria.
• Other: Hyponatremia, impaired wound healing, infertility.

Drug Interactions & Precautions

• Nephrotoxic Drugs (e.g., NSAIDs): Increase renal toxicity risk.
• Cardiotoxic Agents (e.g., Doxorubicin): Potentiate heart damage.
• Live Vaccines: Avoid during treatment due to immunosuppression.
• Alcohol Content: Contains ethanol; may cause dizziness or CNS depression.

Use in Specific Populations

• Pregnancy/Lactation: Category D – teratogenic; advise contraception and avoid breastfeeding.
• Fertility: May cause permanent gonadal suppression.
• Renal Impairment: Reduce dose in CrCl <30 mL/min.

Storage & Packaging

• Storage: Refrigerate at 2–8°C; protect from light and moisture.
• Packaging Options:
  • Cycloph™ 500 Injection: 500 mg/vial (200 mg/mL concentration).

Why Choose Cycloph 500 mg from Saif Pharma?

Saif Pharma is a globally trusted supplier of oncology medications, delivering WHO-GMP-certified chemotherapy drugs to 60+ countries, including the USA, Canada, UAE, and India. Partnering with Eskayef Pharmaceuticals ensures adherence to international quality standards, making Cycloph 500 mg a reliable choice for oncologists.

Conclusion

Cycloph 500 mg (Cyclophosphamide) Injection remains a cornerstone of chemotherapy for hematologic and solid tumors, offering broad-spectrum efficacy with manageable toxicity. For authentic, cost-effective access, trust Saif Pharma—your global partner in oncology care.